NBRV vs. ZNTL, PRQR, CRDF, CYBN, SLN, CGEN, ACRS, LYEL, SCPH, and GNFT
Should you be buying Nabriva Therapeutics stock or one of its competitors? The main competitors of Nabriva Therapeutics include Zentalis Pharmaceuticals (ZNTL), ProQR Therapeutics (PRQR), Cardiff Oncology (CRDF), Cybin (CYBN), Silence Therapeutics (SLN), Compugen (CGEN), Aclaris Therapeutics (ACRS), Lyell Immunopharma (LYEL), scPharmaceuticals (SCPH), and Genfit (GNFT). These companies are all part of the "pharmaceutical products" industry.
Nabriva Therapeutics vs.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.
Zentalis Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 346.43%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Zentalis Pharmaceuticals is more favorable than Nabriva Therapeutics.
In the previous week, Zentalis Pharmaceuticals had 3 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 1 mentions for Nabriva Therapeutics. Zentalis Pharmaceuticals' average media sentiment score of 0.93 beat Nabriva Therapeutics' score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.
Zentalis Pharmaceuticals has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Zentalis Pharmaceuticals' return on equity of -43.91% beat Nabriva Therapeutics' return on equity.
Zentalis Pharmaceuticals has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500.
Nabriva Therapeutics received 334 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. However, 63.44% of users gave Zentalis Pharmaceuticals an outperform vote while only 55.67% of users gave Nabriva Therapeutics an outperform vote.
Nabriva Therapeutics has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.
0.3% of Nabriva Therapeutics shares are owned by institutional investors. 3.6% of Zentalis Pharmaceuticals shares are owned by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Zentalis Pharmaceuticals beats Nabriva Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Nabriva Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nabriva Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NBRV) was last updated on 1/18/2025 by MarketBeat.com Staff
